• Home
  • Search Results
  • Creation of Conductive Graphene Materials by Bacterial Reduction Using Shewanella Oneidensis.

Creation of Conductive Graphene Materials by Bacterial Reduction Using Shewanella Oneidensis.

ChemistryOpen (2019-07-18)
Benjamin A E Lehner, Vera A E C Janssen, Ewa M Spiesz, Dominik Benz, Stan J J Brouns, Anne S Meyer, Herre S J van der Zant
ABSTRACT

Graphene's maximized surface-to-volume ratio, high conductance, mechanical strength, and flexibility make it a promising nanomaterial. However, large-scale graphene production is typically cost-intensive. This manuscript describes a microbial reduction approach for producing graphene that utilizes the bacterium Shewanella oneidensis in combination with modern nanotechnology to enable a low-cost, large-scale production method. The bacterial reduction approach presented in this paper increases the conductance of single graphene oxide flakes as well as bulk graphene oxide sheets by 2.1 to 2.7 orders of magnitude respectively while simultaneously retaining a high surface-area-to-thickness ratio. Shewanella-mediated reduction was employed in conjunction with electron-beam lithography to reduce one surface of individual graphene oxide flakes. This methodology yielded conducting flakes with differing functionalization on the top and bottom faces. Therefore, microbial reduction of graphene oxide enables the development and up-scaling of new types of graphene-based materials and devices with a variety of applications including nano-composites, conductive inks, and biosensors, while avoiding usage of hazardous, environmentally-unfriendly chemicals.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Hydrazine solution, 35 wt. % in H2O
Sigma-Aldrich
Sodium fumarate dibasic, ≥99%

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.